Every year, the US magazine “Time” chooses the 100 most influential people who, according to the editors, have changed the world. The list for 2023 also includes Hidetaka Miyazaki, who last year produced a million-dollar hit with the role-playing game “Elden Ring” that was loved by critics and fans alike.
He royal blue today friday April 14th of 2023 in the informal market it trades at $82,00 for purchase and $87,00 for sale.
The real called blue is the one that circulates in the parallel market, also called the “black” market.
The currency value is usually taller than official due to the fact that it is acquired in banks and that it has an established price.
What to invest 100,000 pesos in and not lose once morest inflation?
According to the blackboard Bank of the Argentine Nation (BNA)the official real today Friday April 14th trades at $42,10 for the purchase now $46,10 for sale.
On average, the Brazilian currency trades at the buying point at $38,28 and in the saleswoman $44,98.
It is the legal tender of Brazil since 1994. Currently, It is the strongest currency in Latin America and the 20th most traded currency worldwide.
The symbol of the Brazilian real is R$ and it currently has the following banknotes: 2, 5, 10, 20, 50 and 100 reales. As for coins, they range from: 5, 10, 25, 50 cents and one real. Previously, in 1942, a first version of the real circulated that was replaced by the real cruzeiro.
Bitcoin: what are the fundamentals behind the cryptocurrency with the most market cap
How much does the dollar and euro blue trade today
In the parallel market, the blue dollar today Friday April 14th trades at $396,00 for purchase and $400,00 for sale.
For his part, he euro blue operates this friday at $426,00 y $430,00 for buying and selling respectively.
Despite the government’s efforts, the blue dollar climbed to $400
How much does the official dollar and euro operate at today
According to the BNA blackboard, the official dollar today friday april 14 trades at $212,75 for the purchase y $220,75 for the sale.
Meanwhile he official euro today opera a $229,75 y $238,75 for buying and selling respectively.
GM/nt
You may also like
Shortage of psychiatrists, dissatisfaction of caregivers, clinical research at half mast, increase in the prevalence of disorders, painful care pathways, sacrificed patients and families in distress, psychiatry is close to the breaking point.
Beyond the inventory and the lack of resources, what kind of psychiatry do we dream of tomorrow? What are the promising innovations?
Surrounded by the best experts – psychiatrists, but also researchers, an epidemiologist, a director of the WHO Mental Health Program, a public prosecutor –, Patrick Lemoine and Boris Cyrulnik debate issues that cannot be ignored today: the prevention of among children and adolescents, excessively prescribed psychotropic drugs, reimbursement of psychologists, recognition of psychiatry as a crossroads discipline, the need to open up to other approaches, even those called “alternatives”.
It is time to make psychiatry a real priority, but also to rebuild and renew it.
SOLANA BEACH, California, April 13, 2023 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global platform company that provides brain navigation and delivery, today announced the successful registration of its Neuro Navigation portfolio with the Brazilian regulatory body, Agência Nacional de Vigilância Sanitária (ANVISA) .
“I had the opportunity to see the ClearPoint Neuro Navigation System in action several times and was thrilled to learn that it was finally approved by the Brazilian regulatory agency,” said Raquel Rodrigues, MD, M.Sc, Pediatric Neurosurgeon and Neuro-oncologist in Brazil. “With a very intuitive interface and software, I personally believe that it is easy to manage its features, even for a neurosurgeon only trained in traditional neuro navigation methods. With ClearPoint we plan, for the first time in Latin America, to offer our patients unprecedented medical treatments, such as Convection Enhanced Delivery (CED) for brain cancer and neurodegenerative disorders with intra-procedural guidance by magnetic resonance imaging. Furthermore, with this system we hope to refine our DBS implants, deep brain biopsies and laser ablations. I am honored to lead the neurosurgical team that will perform the first neurosurgery with this splendid technology here in Brazil”.
“We are incredibly proud to have achieved ANVISA approval following an extensive review,” explained Megan Faulkenberry, Vice President of Quality at ClearPoint Neuro. “Our first approval in Latin America is an important milestone that supports our 4th pillar of growth: international expansion”. Every global approval we gain helps us and our pharmaceutical partners deliver new therapies, both clinically and in clinical trials, to patients with some of the most devastating neurological diseases.”
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore the quality of life for patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and drug delivery, biology, and brain gene therapy. The ClearPoint® Neuro Navigation System is FDA cleared, CE marked, and installed in over 65 locations in North America, Europe, and South America. ClearPoint Neuro partners with more than 50 biological/pharmaceutical companies, academic centers, and contract research organizations, providing solutions for the direct delivery of CNS therapeutics in preclinical studies and clinical trials worldwide. To date, over 6,000 procedures have been performed and supported by the company’s team of clinical experts, who provide support and services to our customers and partners. For more information, please visit www.clearpointneuro.com.
Forward-looking Statements
Statements in this press release regarding the Company’s plans, growth and strategies may be forward-looking statements within the context of federal securities laws. Statements regarding the Company’s future events, developments and future performance, the size of the total addressable markets or market opportunity for the Company’s products and services, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future , are forward-looking statements within the meaning of these laws. Uncertainties and risks might cause the Company’s actual results to differ materially from those expressed or implied by forward-looking statements. Particular uncertainties and risks include those related to: the impact of the COVID-19 pandemic, global instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenues from sales of the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the Company’s ability to market, market and achieve broader market acceptance of the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the ability of our biological partners and drug distributors to achieve commercial success, including the use of our products and services in their delivery of therapies; and risks inherent in the research, development and regulatory approval of new products. More detailed information regarding these and additional factors that might affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with Securities and Exchange Commission.
An image accompanying this announcement is available at
Contato: Contato para os media – ClearPoint Neuro Jacqueline Keller, Vice-presidente de Marketing 949-900-6833 [email protected] Relações com Investidores – ClearPoint Neuro Caroline Corner, PhD ICR Westwicke [email protected]
GLOBENEWSWIRE (Distribution ID 8804250)